Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Cancer of Kidney and Renal PelvisCancer of Liver

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure

Trial Locations (1)

Uppsala University Hospital, Uppsala

All Listed Sponsors

lead

Uppsala University Hospital

OTHER

NCT02016391 - Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours | Biotech Hunter | Biotech Hunter